We assign a fundamental rating of 3 out of 10 to BOLD. BOLD was compared to 525 industry peers in the Biotechnology industry. While BOLD has a great health rating, there are worries on its profitability. BOLD is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year BOLD has reported negative net income.
BOLD had a negative operating cash flow in the past year.

1.2 Ratios

With a decent Return On Assets value of -36.60%, BOLD is doing good in the industry, outperforming 60.95% of the companies in the same industry.
Looking at the Return On Equity, with a value of -56.06%, BOLD is in the better half of the industry, outperforming 64.19% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-36.6%
ROE	-56.06%
ROIC	N/A

ROA(3y)-43.16%

ROA(5y)N/A

ROE(3y)-51.23%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BOLD so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for BOLD has been increased compared to 1 year ago.
BOLD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -2.31, we must say that BOLD is in the distress zone and has some risk of bankruptcy.
BOLD has a Altman-Z score (-2.31) which is comparable to the rest of the industry.
BOLD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-2.31

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 10.14 indicates that BOLD has no problem at all paying its short term obligations.
The Current ratio of BOLD (10.14) is better than 81.33% of its industry peers.
BOLD has a Quick Ratio of 10.14. This indicates that BOLD is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 10.14, BOLD belongs to the best of the industry, outperforming 81.33% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	10.14
Quick Ratio	10.14

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BOLD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -484.97%.

EPS 1Y (TTM)-484.97%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%16.22%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

BOLD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.46% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y82.65%

EPS Next 2Y36.1%

EPS Next 3Y24.46%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BOLD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BOLD. No positive earnings are expected for the next year.